Current stock page

Catalysts

KRYS Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

KRYSKrystal Biotech, Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 8/10
$305.23−$0.45 (−0.15%)

Latest quote

  • Momentum
    58
  • Value
    67
  • Quality
    83
  • Risk resilience
    69
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 16, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 69/100

Momentum 58/100 and sentiment — before the next covered event.

Recent coverage
4 articles

Updated Nov 15, 2026 · Sentiment 9.78%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 58/100AIQ Edge 8/10 Strong Relative Position
Beat rate
88%
7 of 8 reported periods
Average surprise
+26.6%
Across covered historical reports
Latest result
+14.5%
Nov 2, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 2, 2026—$1.79$2.05+14.5%$125.77M$127.34M
Aug 3, 2026—$1.70$1.79+5.3%$120.93M$119.22M
May 4, 2026—$1.45$1.83+26.2%$112.11M$116.36M
Feb 17, 2026—$1.62$1.70+4.9%$105.35M$107.11M
Nov 3, 2025—$1.12$2.66+137.5%$105.3M$97.8M
Aug 4, 2025—$1.08$1.29+19.4%$95.41M$96.04M
May 6, 2025—$1.38$1.20-13.0%$105.98M$88.18M
Feb 19, 2025—$1.29$1.52+17.8%$91.35M$91.14M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
11
Buy
1
Hold
12-month analyst target
$428.50
+40.39% versus current price
Based on 12 analyst observations. Targets are estimates, not predictions.
Low target
$416.00
+36.29% vs latest price
Average target
$428.50
+40.39% vs latest price
High target
$441.00
+44.48% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 16, 2027

Next known earnings or reporting date.

EPS estimate$2.04

Current analyst expectation for the upcoming report.

Revenue estimate$134.02M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score58

Where event reaction would show up first.

AIQ score69/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
12
Average target
$428.50
Target upside
40.39%
Target range
$416.00 - $441.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
1
Neutral
3
Negative
0
seekingalpha.com · Nov 2, 2026

Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call Transcript

Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call November 2, 2026 8:30 AM ESTCompany ParticipantsStephane Paquette - Senior Vice President of Corporate...

zacks.com · Nov 2, 2026

Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates

Krystal Biotech (KRYS) delivered earnings and revenue surprises of +11.41% and +2.16%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

zacks.com · Oct 26, 2026

Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for

Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

gurufocus.com · Sep 24, 2026

KRYS Reinstated by Goldman Sachs -- Price Target Announced at $441

Krystal Biotech (KRYS) Analyst Rating Update On October 5, 2023, Goldman Sachs reinstated coverage on Krystal Biotech (KRYS) with a 'Buy' rating. The investm

Open full news and sentiment

KRYS Catalysts FAQ

What are the next catalysts for KRYS stock?

KRYS's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move KRYS stock?

Upcoming events that could move KRYS include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could KRYS's next earnings report affect the stock?

KRYS's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive KRYS stock higher?

KRYS could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt KRYS stock?

KRYS could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.